COVID-19 and Breast Cancer Prognosis: A Comparative Analysis of Disease-Free Survival Rates in Taiwan.

IF 2.6 4区医学 Q3 ONCOLOGY

Cancer Management and Research Pub Date : 2025-10-04 eCollection Date: 2025-01-01 DOI:10.2147/CMAR.S539849

Wei-Teng Wang, Pei-Shan Wu, Wan-Chi Hu, Chen-Pin Chou

{"title":"COVID-19 and Breast Cancer Prognosis: A Comparative Analysis of Disease-Free Survival Rates in Taiwan.","authors":"Wei-Teng Wang, Pei-Shan Wu, Wan-Chi Hu, Chen-Pin Chou","doi":"10.2147/CMAR.S539849","DOIUrl":null,"url":null,"abstract":"Purpose: This study evaluates the effect of pandemic-related diagnostic and treatment delays on 3-year disease-free survival (DFS) in Taiwanese breast cancer patients.Material and methods: This single-institution study analyzed breast cancer patients across three distinct periods: non-COVID-19 in 2017, pre-COVID-19 in 2019, and during the COVID-19 pandemic in 2020, to investigate the impact of the COVID-19 pandemic on DFS rates and recurrence rates. DFS was defined as the interval from surgery to the occurrence of breast cancer recurrence or death, whereas overall survival (OS) was defined as the interval from surgery to death from any cause. Follow-up protocol included regular clinical examinations and annual imaging, with a minimum follow-up of 36 months unless an event occurred earlier.Results: The demographics of breast cancer patients changed from 2017 to 2020, with an average age increasing from 54.6 to 58.6 years. While overall survival (OS) did not vary significantly across the cohorts, DFS differed significantly, with the 2020 cohort experiencing a significant decline in DFS compared to 2017 (p = 0.027). Recurrence rates also increased, from 3.1% in 2017 to 7.6% in 2020.Conclusion: The COVID-19 pandemic had a negative impact on the DFS of breast cancer patients, with the 2020 cohort experiencing a significantly shorter DFS time compared to the 2017 cohort.","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"2287-2295"},"PeriodicalIF":2.6000,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12506798/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Management and Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/CMAR.S539849","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study evaluates the effect of pandemic-related diagnostic and treatment delays on 3-year disease-free survival (DFS) in Taiwanese breast cancer patients.

Material and methods: This single-institution study analyzed breast cancer patients across three distinct periods: non-COVID-19 in 2017, pre-COVID-19 in 2019, and during the COVID-19 pandemic in 2020, to investigate the impact of the COVID-19 pandemic on DFS rates and recurrence rates. DFS was defined as the interval from surgery to the occurrence of breast cancer recurrence or death, whereas overall survival (OS) was defined as the interval from surgery to death from any cause. Follow-up protocol included regular clinical examinations and annual imaging, with a minimum follow-up of 36 months unless an event occurred earlier.

Results: The demographics of breast cancer patients changed from 2017 to 2020, with an average age increasing from 54.6 to 58.6 years. While overall survival (OS) did not vary significantly across the cohorts, DFS differed significantly, with the 2020 cohort experiencing a significant decline in DFS compared to 2017 (p = 0.027). Recurrence rates also increased, from 3.1% in 2017 to 7.6% in 2020.

Conclusion: The COVID-19 pandemic had a negative impact on the DFS of breast cancer patients, with the 2020 cohort experiencing a significantly shorter DFS time compared to the 2017 cohort.

Abstract Image

查看原文本刊更多论文

新冠肺炎与乳腺癌预后：台湾地区无病生存率的比较分析

目的：本研究评估大流行相关的诊断和治疗延迟对台湾乳腺癌患者3年无病生存（DFS）的影响。材料和方法：本单机构研究分析了2017年非COVID-19、2019年COVID-19前期和2020年COVID-19大流行期间三个不同时期的乳腺癌患者，以调查COVID-19大流行对DFS率和复发率的影响。DFS定义为从手术到乳腺癌复发或死亡的时间间隔，而总生存期（OS）定义为从手术到任何原因死亡的时间间隔。随访方案包括定期临床检查和年度影像学检查，至少随访36个月，除非事件发生较早。结果：2017年至2020年，乳腺癌患者的人口结构发生了变化，平均年龄从54.6岁增加到58.6岁。虽然各队列的总生存期（OS）没有显著差异，但DFS差异显著，与2017年相比，2020年队列的DFS显著下降（p = 0.027）。复发率也从2017年的3.1%上升到2020年的7.6%。结论：2019冠状病毒病大流行对乳腺癌患者的DFS产生了负面影响，与2017年队列相比，2020年队列的DFS时间明显缩短。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Management and Research Medicine-Oncology

CiteScore

7.40

自引率

0.00%

发文量

448

审稿时长

16 weeks

期刊介绍： Cancer Management and Research is an international, peer reviewed, open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for cancer patients. Specific topics covered in the journal include: ◦Epidemiology, detection and screening ◦Cellular research and biomarkers ◦Identification of biotargets and agents with novel mechanisms of action ◦Optimal clinical use of existing anticancer agents, including combination therapies ◦Radiation and surgery ◦Palliative care ◦Patient adherence, quality of life, satisfaction The journal welcomes submitted papers covering original research, basic science, clinical & epidemiological studies, reviews & evaluations, guidelines, expert opinion and commentary, and case series that shed novel insights on a disease or disease subtype.